Nusinersen
- TRADE NAME: Spinraza (Biogen)
- INDICATIONS: Spinal muscular atrophy
- CLASS: Survival motor neuron-2 (SMN2)-directed antisense oligonucleotide
- HALF-LIFE: 63–87 days (in plasma)
FDA APPROVAL DATE: 12/23/2016
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
No data available
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 02/17/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric